Have Amylyx Pharmaceuticals Insiders Been Selling Stock?
Amylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
How this was made
The 30-second read
Why it matters
The disclosed Form 4 filing provides fresh data on insider holdings, but the modest transaction size limits material impact.
Market read
Small‑scale insider sale; limited trading relevance.
What to watch
Insider retains 99.1% ownership and remains invested, which may offset negative perception.
Background
Amylyx Pharmaceuticals (NASDAQ: AMYX) is a biotech focused on rare neurological diseases. Insider activity is often monitored for signals.
Market effects
Minimal; biotech sector unlikely to react broadly to a single insider sale.
None; the event is company‑specific.
Negligible.
Counterpoint
The sale could be a strategic rebalancing rather than a lack of confidence, so price may stay stable.
Key entities
- IndividualJoshua Cohen
Co‑Founder and insider of Amylyx Pharmaceuticals.
